NEW YORK, Oct. 2 – Cellomics of Pittsburgh said Tuesday it sold its ArrayScan High Content Screening system to Serono Pharmaceutical Research Institute, a subsidiary of Serono International of Switzerland.
Financial terms of the deal were not disclosed.
The ArrayScan HCS system analyzes how potential drugs affect cells by automatically imaging whether cellular probes fluoresce. The system, which Cellomics said has been placed in nine of the top 10 pharmaceutical companies in the world, is compatible with both 96 and 384 well microtitre plates.
"The ArrayScan HCS System will enable us to increase our efficiency, accuracy, and output of cell-based biological tests for small molecule and therapeutic protein discovery projects," Anthony Nichols, SPRI cellular pharmacology group leader, said in a statement.
Beckman Coulter is the exclusive distributor of Cellomics' ArrayScan HCS System, Cellomics' KineticScan HCS Reader, and Cellomics' Informatics Solutions.